Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Auxilium Signs Sobi As Pfizer Replacement In Europe

This article was originally published in The Pink Sheet Daily

Executive Summary

The maker of Xiaflex/Xiapex has found a new commercialization partner in the EU after its first partnership fell apart due to disappointing sales of the drug in those territories.

You may also be interested in...

Pending EU Approval Of Eloctate, Sobi Opts In To Second Hemophilia Program With Biogen

Sobi also gets two oral formulations of Orfadin for the rare genetic disorder HT-1 and is starting over with a new candidate in a collaboration with Affibody.

Auxilium Revamps Commercial Strategy For Xiaflex

The manufacturer expected Xiaflex to take off as a non-invasive, more effective alternative to hand surgery, but the market has been slow to convert, prompting Auxilium to shift around its commercial organization.

IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic

Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.


Related Companies

Related Deals

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts